Business Context and Reporting Period
This Form 8-K is a Current Report filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc., as indicated in the metadata) on December 6, 2023. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, NJ. The filing serves as a Regulation FD disclosure to make a business presentation available to the public.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to distribute presentation materials and does not contain a financial statement or earnings data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing solely announces the availability of a presentation regarding the Company's business.
Guidance, Outlook, and Risks
- Management Commentary: The Company has released a presentation (Exhibit 99.1) containing summary information about its business.
- Forward-Looking Statements: The presentation contains forward-looking statements. The Company explicitly disclaims any obligation to update these statements to reflect future events or circumstances.
- Legal Disclaimers: The information in the presentation is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual company name is Tharimmune, Inc. (Ticker: THAR), not Canton Strategic Holdings, Inc.
- Review Exhibit 99.1 (Presentation Materials) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm the date of the forward-looking statements is December 6, 2023, and note that the Company is under no obligation to update them.
- Check the signature block, which lists Randy Milby as the Chief Executive Officer signing on behalf of the registrant (noted as Hillstream BioPharma, Inc. in the signature line, suggesting a potential name change or administrative discrepancy in the source text).